Maimon Yossi 4
4 · Protalix BioTherapeutics, Inc. · Filed May 4, 2012
Insider Transaction Report
Form 4
Maimon Yossi
VP, Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2012-05-02$0.97/sh+75,964$73,837→ 75,964 total(indirect: By Trust) - Sale
Common Stock
2012-05-02$7.13/sh−125,964$898,123→ 0 total(indirect: By Trust) - Exercise/Conversion
Stock Options (Right to Buy)
2012-05-02−50,000→ 0 totalExercise: $2.65Exp: 2019-02-25→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2012-05-02$2.65/sh+50,000$132,500→ 125,964 total(indirect: By Trust) - Exercise/Conversion
Stock Options (Right to Buy)
2012-05-02−75,964→ 0 totalExercise: $0.97Exp: 2016-09-19→ Common Stock (75,964 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- [F3]All options are fully vested.
- [F4]Does not include (i) options to purchase 175,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018 and (ii) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.